Skip to main content
HELP
NASDAQ Life Sciences

CEO Michael Halstead Buys $1.35M of Cybin Stock at $13.47

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$13.67
Mkt Cap
$1.37M
52W Low
$3.76
52W High
$15.15
52W Position info
264% above low
Off High info
9.8% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

HELP has more than doubled off its 52-week low of $3.76.

Summary

Cybin CEO Michael Halstead purchased $1.35M of company stock on the open market, a significant insider buy that nearly equals the company's entire market cap.


Key Events · Ownership and Investor Activity · HELP

  • CEO Buys $1.35M in Open Market

    Michael Halstead purchased 100,000 shares at $13.47 per share for a total of $1,347,050 on September 21, 2026.

  • Purchase Nearly Equals Market Cap

    The transaction value of $1.35M represents approximately 98% of the company's $1.37M market cap, an extraordinary personal commitment.

  • Follows Insider Buying Cluster

    This purchase follows three consecutive open-market buys by Chief Growth Officer Paul Glavine totaling $3.47M between September 9-11, 2026.

  • Post-Transaction Holdings

    Halstead now directly owns 168,568 shares following the purchase.


Analysis · HELP · Life Sciences

CEO Michael Halstead bought 100,000 shares on the open market for $1,347,050 at $13.47 per share. This is a massive personal bet by the top executive, representing nearly the entire market cap of the company. It follows a series of large insider purchases by the Chief Growth Officer earlier this month, signaling strong internal conviction in the company's prospects despite recent heavy cash burn and a $50M dilutive offering in June.

How filings like this one have moved

In the 30 days to Oct 22, 2026, 46.1% of the 284 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HELP was trading at $13.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $3.76 to $15.15. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HELP - Latest Insights

HELP
Oct 21, 2026, 4:33 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $10.89
Real-time Price: $10.70 info
Change: -$0.190 (-2%) info
Market Cap: $1.362M info
HELP
Oct 01, 2026, 8:13 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $11.65
Real-time Price: $10.70 info
Change: -$0.950 (-8%) info
Market Cap: $1.362M info
HELP
Sep 11, 2026, 9:03 AM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $13.10
Real-time Price: $10.70 info
Change: -$2.40 (-18%) info
Market Cap: $1.362M info
HELP
Sep 10, 2026, 6:21 AM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $13.88
Real-time Price: $10.70 info
Change: -$3.18 (-23%) info
Market Cap: $1.362M info
HELP
Sep 10, 2026, 6:19 AM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $13.70
Real-time Price: $10.70 info
Change: -$3.00 (-22%) info
Market Cap: $1.362M info